Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

This is a Phase I, combination of single ascending dose/multiple ascending dose to evaluate the safety and pharmacokinetics of birinapant as a single agent in patients infected with chronic Hepatitis B virus.

Next Previous
Trial Profile

This is a Phase I, combination of single ascending dose/multiple ascending dose to evaluate the safety and pharmacokinetics of birinapant as a single agent in patients infected with chronic Hepatitis B virus.

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 07 Aug 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Birinapant (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors TetraLogic Pharmaceuticals

Most Recent Events

  • 07 Aug 2015 According to the media release of TetraLogic pharmaceuticals, this study is expect to initiate at multiple sites in India in early 2016 and the timing of results will depend upon enrollment rates.
  • 07 Aug 2015 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top